AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between August 31, 2026, and September 3, 2026, for AIM Immunotech Inc., a Delaware corporation trading on NYSE American under the symbol "AIM". The filing details the resolution of a material debt obligation through a debt-for-equity exchange.
Key Financial Metrics and Transaction Details
- Debt Resolution: The Company satisfied a Promissory Note dated February 16, 2024, in full.
- Debt Converted: Approximately $1,224,341 of principal was converted into equity.
- Equity Issued: 5,065,840 shares of common stock were issued to the lender, Streeterville Capital, LLC.
- Conversion Price: The average conversion price was approximately $0.24 per share.
- Remaining Debt: As of September 3, 2026, no amounts remain owing under the Promissory Note.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or overall liquidity metrics for the period; it focuses exclusively on the debt restructuring transaction.
Material Changes Versus Prior Period
The primary material change is the elimination of the $1,224,341 promissory note liability from the Company's balance sheet, replaced by an increase in outstanding common shares. This transaction was executed following stockholder approval at a special meeting held on July 15, 2026, in compliance with NYSE American Company Guide Sections 713(a) and 713(b).
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction. The issuance of the Exchange Shares was conducted under the exemption from registration requirements provided by Section 3(a)(9) of the Securities Act of 1933, as no commission was paid for soliciting the exchange.
Key Facts for Investor Verification
- Verify the exact number of shares issued (5,065,840) and the resulting total share count post-transaction.
- Confirm the full satisfaction of the February 16, 2024 Promissory Note and the absence of any remaining accrued interest or fees.
- Review the Form 10-Q for the period ended June 30, 2026, for broader financial context regarding the Company's liquidity prior to this debt conversion.
- Examine Exhibit 10.1 (Form of Exchange Agreement) for specific terms regarding the partitioned promissory notes.